Corbus Pharmaceuticals (CRBP) Q3 2026 earnings summary

Executive summary

• Pipeline centers on sutantatug envedotin for Nectin-4-expressing tumors and CRB-913 for obesity; no product revenue generated to date.

• TEMPO-1 began dosing in Phase 3 for 2L+ OPSCC, while CANYON-1 reported positive topline weight-loss results for CRB-913.

Financial highlights

• Q3 operating expenses were $38.824M vs. $24.417M YoY; R&D was $34.247M vs. $20.860M and G&A was $4.577M vs. $3.557M.

• Q3 net loss was $37.754M vs. $23.342M; 9M net loss was $95.760M vs. $57.982M.

• Q3 expense growth was primarily driven by a $15.0M sutantatug envedotin milestone under the CSPC license and higher clinical costs.

• 9M operating cash use was $76.4M; financing provided $27.6M, mainly through common-stock sales under the Open Market Sale Agreement.

Outlook and guidance

• Cash, cash equivalents and investments of $115.3M at Sept. 30, 2026, were expected to fund operations for at least 12 months from filing and into 2028 under current plans.

• Sutantatug envedotin plus Keytruda first-line OPSCC data are anticipated in Q1 2027; CRB-913 development plans are to be discussed with FDA, with a potential GLP-1 combination also under evaluation.

• Significant expenses and operating losses are expected for several years as clinical and preclinical development, research and manufacturing continue.